These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16609060)

  • 1. Chemotherapy and targeted therapy combinations in advanced melanoma.
    Flaherty KT
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
    Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
    Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic chemotherapy.
    Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
    Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets in melanoma from angiogenesis to apoptosis.
    Sosman JA; Puzanov I
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of metastatic melanoma.
    Tawbi HA; Kirkwood JM
    Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Tran MA; Smith CD; Kester M; Robertson GP
    Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for metastatic melanoma: time for a change?
    Gogas HJ; Kirkwood JM; Sondak VK
    Cancer; 2007 Feb; 109(3):455-64. PubMed ID: 17200963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and biologic therapies for melanoma: do they work?
    Jilaveanu LB; Aziz SA; Kluger HM
    Clin Dermatol; 2009; 27(6):614-25. PubMed ID: 19880049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
    Hartmann JT
    Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
    Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR
    Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel combinations based on epidermal growth factor receptor inhibition.
    Adjei AA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted molecular therapy in melanoma.
    Puzanov I; Flaherty KT
    Semin Cutan Med Surg; 2010 Sep; 29(3):196-201. PubMed ID: 21051014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.